Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the rare genetic condition Duchenne muscular dystrophy. A young man with ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 in Gene Therapy suggests the body’s natural immune system might be ...

The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy community. The patient died from acute liver failure months after starting ...

following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy (DMD) gene therapy Elevidys.

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy ... after the recent patient death due to ...